Global Fruquintinib Market Strategic Research Report

Scope of the Report

The global Fruquintinib market size is predicted to grow from US$ 456 million in 2025 to US$ 1,375 million in 2032; it is expected to grow at a CAGR of 15.6% from 2026 to 2032.

In 2025, global production of fruquintinib reached approximately 810,000 units.Fruquintinib is an oral small-molecule highly selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, primarily used for the treatment of various solid tumors, with demonstrated efficacy particularly in metastatic colorectal cancer. It exerts its anti-tumor effects by selectively inhibiting VEGFR-1, VEGFR-2, and VEGFR-3 signaling pathways, thereby blocking angiogenesis and suppressing tumor growth and metastasis. Fruquintinib is characterized by high target selectivity, convenient oral administration, and good tolerability, making it clinically valuable in the treatment of advanced cancers, especially in later-line therapy settings.

Fruquintinib, as a highly selective VEGFR tyrosine kinase inhibitor, holds an important position in the oncology targeted therapy market, particularly demonstrating strong competitiveness in the later-line treatment of metastatic colorectal cancer. With the continuous rise in cancer incidence and the widespread adoption of precision medicine, the demand for anti-angiogenic therapies continues to grow, providing a stable market foundation for this drug. From a competitive landscape perspective, anti-angiogenic monoclonal antibodies such as Bevacizumab and small-molecule multi-target TKIs such as Regorafenib dominate the market. However, fruquintinib, with its high selectivity, favorable safety profile, and clear clinical benefits, has established differentiated advantages in later-line treatment settings. On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although volume-based procurement and healthcare cost-control policies continue to exert downward pressure on pricing. From a competitive standpoint, the emergence of various anti-angiogenic therapies and combination regimens with immunotherapy from both domestic and international players is intensifying market competition. Therefore, the future market performance of fruquintinib will depend on its progress in expanding indications (such as gastric cancer and lung cancer), developing combination strategies, and accumulating real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and cost.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Fruquintinib market?

What factors are driving Fruquintinib market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Fruquintinib market opportunities vary by end market size?

How does Fruquintinib break out by Type, by Application?

This report presents a comprehensive overview of the global Fruquintinib market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 1 mg capsule
• 5 mg capsule

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• Metastatic Colorectal Cancer (mCRC)
• Inhibit Tumor Angiogenesis
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Fruquintinib market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Metastatic Colorectal Cancer (mCRC), Inhibit Tumor Angiogenesis, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact